ClinicalTrials.gg
RecruitingNCT06490952Updated Jul 8, 2024

Study of Health Behavior in Patients After Heart Valve Replacement: Longitudinal Studies

An observational study in Heart Valve Diseases, Health Behavior and Postoperative Period, sponsored by Fujian Medical University Union Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2024-07-08.

Sponsored by Fujian Medical University Union Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2024, 2 years ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
219
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Heart Valve Diseases with a site in China — 28 open to participants now, 30 under way, none of them phase 3. Heart Valve Diseases · China.

Planned enrollment
31st of 35
219 · median 3,000
Started
2024
with 8 others
Observational
35 of 69
17 open now
Primary completion
2024-11
later than 4 of 29 live
Registered
56th of 69
by date

Among the 69 studies in Heart Valve Diseases with a site in China, this one is the 31st largest by planned enrollment of the 35 observational ones that give a count, is one of 9 that started in 2024, is one of 35 observational ones, reaches primary completion later than 4 of the 29 other live ones, and was the 56th registered.

Heart Valve Diseases

557 studies on the registry are indexed under Heart Valve Diseases; 167 are open to participants now.

Browse Heart Valve Diseases studies →

Open to participants now

28 of the 69 studies in Heart Valve Diseases with a site in China are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 119 Heart Valve Diseases studies recruiting now, 94 (79%) set no upper age limit and 10 (8%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Heart Valve Diseases with a site in China, or all of them as a file.
02

Study summary

To investigates the influencing factors and the pathways of health behavior in patients after heart valve replacement.

Read the detailed description

Currently, the prevalence of heart valve disease is 2.0% to 13.2%, and heart valve replacement is the most important treatment to address heart valve disease. Heart valve replacement surgery is highly traumatic and risky, and the recovery of physiological, psychological, and social functions of postoperative patients is challenging, affecting the recovery process of patients. Healthy behavior is a lifestyle that can effectively reduce risk factors for adverse events and complications at the physiological, psychological, and social levels to slow disease progression, which can help promote patient recovery and improve prognosis. Therefore, this study investigates and analyzes the health behaviors of postoperative patients in different periods, explores their influencing factors and analyzes their pathways of action.

03

Conditions studied

  • Heart Valve Diseases
  • Health Behavior
  • Postoperative Period
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients undergoing postoperative heart valve replacement were selected for the study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years;
  2. VHD diagnosed by echocardiography;
  3. Received HVR treatment;
  4. able to communicate normally.

Exclusion criteria

Exclusion Criteria:

  1. Those with a conscious disorder or mental illness;
  2. Those with severe organic diseases or comorbidities;
  3. Those with cardiac function class IV;
  4. Those who could not complete the questionnaire correctly independently or under the guidance of the researcher.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
219 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Health behavior

    A set of behavioral activities undertaken by an individual to promote or maintain health.

    Time frame: At 1-2 days before discharge, at 1 month after discharge, at 3 month after discharge, at 6 month after discharge.

Secondary outcomes

  1. Social support

    Support received by an individual from within a social relationship.

    Time frame: At 1-2 days before discharge, at 1 month after discharge, at 3 month after discharge, at 6 month after discharge.

  2. Anxiety and depression

    Measuring the psychological situation.

    Time frame: At 1-2 days before discharge, at 1 month after discharge, at 3 month after discharge, at 6 month after discharge.

  3. Self-efficacy

    Measure the level of self-confidence.

    Time frame: At 1-2 days before discharge, at 1 month after discharge, at 3 month after discharge, at 6 month after discharge.

  4. Medication Literacy

    Measuring medication-taking skills.

    Time frame: At 1-2 days before discharge, at 1 month after discharge, at 3 month after discharge, at 6 month after discharge.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Nov 2024, 10 months after the start.

Of 96 non-industry observational studies under Heart Valve Diseases, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 212. This study's planned 10 months is below that.

Counting every sponsor, half of 116 studies reached it within 67 months; a quarter within 29 and three quarters within 212.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2024
First posted
Jul 8, 2024
StartActual
Jan 1, 2024
Primary completionEst.
Nov 1, 2024
CompletionEst.
Dec 1, 2024
Last update
Jul 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06490952
Responsible party
Sponsor
First posted
Jul 8, 2024
Start date
Jan 1, 2024
Primary completion
Nov 1, 2024 (estimated)
Completion
Dec 1, 2024 (estimated)
Last update
Jul 8, 2024

Study contacts

Yanjuan Lin
Contact
fjxhyjl@163.com
+86 591 8621 8336
Yanjuan Lin
study chair · Fujian Medical University Union Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion